PTC Therapeutics (PTCT) Competitors

$69.79 -1.23 (-1.73%)

Closing price 04:00 PM Eastern

Extended Trading

$69.76 -0.03 (-0.04%)

As of 04:14 PM Eastern

PTCT vs. INSM, BNTX, ROIV, MRNA, and VTRS

Should you buy PTC Therapeutics stock or one of its competitors? MarketBeat compares PTC Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PTC Therapeutics include Insmed (INSM), BioNTech (BNTX), Roivant Sciences (ROIV), Moderna (MRNA), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry.

How does PTC Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Insmed currently has a consensus price target of $210.95, suggesting a potential upside of 92.60%. PTC Therapeutics has a consensus price target of $88.36, suggesting a potential upside of 26.60%. Given Insmed's stronger consensus rating and higher possible upside, research analysts clearly believe Insmed is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
PTC Therapeutics	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.57

PTC Therapeutics has higher revenue and earnings than Insmed. PTC Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	39.15	-$1.28B	-$5.75	N/A
PTC Therapeutics	$1.73B	3.35	$682.64M	-$2.33	N/A

In the previous week, Insmed had 8 more articles in the media than PTC Therapeutics. MarketBeat recorded 16 mentions for Insmed and 8 mentions for PTC Therapeutics. Insmed's average media sentiment score of 1.16 beat PTC Therapeutics' score of 0.60 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
PTC Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insmed has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

PTC Therapeutics has a net margin of -22.58% compared to Insmed's net margin of -144.44%. Insmed's return on equity of -130.11% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-144.44%	-130.11%	-51.57%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Summary

Insmed beats PTC Therapeutics on 9 of the 14 factors compared between the two stocks.

How does PTC Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

BioNTech currently has a consensus target price of $130.60, suggesting a potential upside of 43.63%. PTC Therapeutics has a consensus target price of $88.36, suggesting a potential upside of 26.60%. Given BioNTech's stronger consensus rating and higher probable upside, research analysts clearly believe BioNTech is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
PTC Therapeutics	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.57

PTC Therapeutics has a net margin of -22.58% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

BioNTech has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

PTC Therapeutics has lower revenue, but higher earnings than BioNTech. PTC Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.08	-$1.29B	-$5.88	N/A
PTC Therapeutics	$1.73B	3.35	$682.64M	-$2.33	N/A

In the previous week, PTC Therapeutics had 4 more articles in the media than BioNTech. MarketBeat recorded 8 mentions for PTC Therapeutics and 4 mentions for BioNTech. PTC Therapeutics' average media sentiment score of 0.60 beat BioNTech's score of 0.33 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PTC Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioNTech beats PTC Therapeutics on 11 of the 16 factors compared between the two stocks.

How does PTC Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Roivant Sciences has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market. Comparatively, PTC Therapeutics has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market.

In the previous week, Roivant Sciences had 11 more articles in the media than PTC Therapeutics. MarketBeat recorded 19 mentions for Roivant Sciences and 8 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.60 beat Roivant Sciences' score of 0.40 indicating that PTC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	2 Very Positive mention(s)	5 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
PTC Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Roivant Sciences presently has a consensus target price of $33.05, indicating a potential upside of 7.01%. PTC Therapeutics has a consensus target price of $88.36, indicating a potential upside of 26.60%. Given PTC Therapeutics' higher probable upside, analysts clearly believe PTC Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
PTC Therapeutics	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.57

64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by insiders. Comparatively, 5.5% of PTC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PTC Therapeutics has higher revenue and earnings than Roivant Sciences. PTC Therapeutics is trading at a lower price-to-earnings ratio than Roivant Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$29.05M	760.79	-$171.98M	-$1.17	N/A
PTC Therapeutics	$1.73B	3.35	$682.64M	-$2.33	N/A

PTC Therapeutics has a net margin of -22.58% compared to Roivant Sciences' net margin of -6,079.94%. Roivant Sciences' return on equity of -19.04% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-6,079.94%	-19.04%	-18.15%
PTC Therapeutics	-22.58%	-362.45%	-6.76%

Summary

Roivant Sciences beats PTC Therapeutics on 10 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Moderna?

PTC Therapeutics (NASDAQ:PTCT) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

PTC Therapeutics presently has a consensus price target of $88.36, suggesting a potential upside of 26.60%. Moderna has a consensus price target of $35.73, suggesting a potential downside of 24.39%. Given PTC Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe PTC Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.57
Moderna	5 Sell rating(s)	12 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.84

75.3% of Moderna shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PTC Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

In the previous week, Moderna had 3 more articles in the media than PTC Therapeutics. MarketBeat recorded 11 mentions for Moderna and 8 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.60 beat Moderna's score of 0.01 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

PTC Therapeutics has higher earnings, but lower revenue than Moderna. PTC Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.35	$682.64M	-$2.33	N/A
Moderna	$1.94B	9.65	-$2.82B	-$8.15	N/A

PTC Therapeutics has a net margin of -22.58% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Moderna	-143.55%	-26.64%	-19.32%

Summary

PTC Therapeutics beats Moderna on 9 of the 17 factors compared between the two stocks.

How does PTC Therapeutics compare to Viatris?

PTC Therapeutics (NASDAQ:PTCT) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

PTC Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.35	$682.64M	-$2.33	N/A
Viatris	$14.30B	1.34	-$3.51B	-$0.26	N/A

PTC Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Viatris has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

PTC Therapeutics currently has a consensus target price of $88.36, suggesting a potential upside of 26.60%. Viatris has a consensus target price of $16.43, suggesting a potential downside of 0.19%. Given PTC Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe PTC Therapeutics is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.57
Viatris	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Viatris has a net margin of -2.04% compared to PTC Therapeutics' net margin of -22.58%. Viatris' return on equity of 19.04% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Viatris	-2.04%	19.04%	7.62%

79.9% of Viatris shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 0.3% of Viatris shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, PTC Therapeutics had 3 more articles in the media than Viatris. MarketBeat recorded 8 mentions for PTC Therapeutics and 5 mentions for Viatris. PTC Therapeutics' average media sentiment score of 0.60 beat Viatris' score of 0.07 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viatris	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PTC Therapeutics beats Viatris on 10 of the 17 factors compared between the two stocks.

Get PTC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PTCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PTCT vs. The Competition

Export

Metric	PTC Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.79B	$3.36B	$6.34B	$12.29B
Dividend Yield	N/A	2.32%	2.80%	5.36%
P/E Ratio	-29.95	19.01	20.94	25.47
Price / Sales	3.35	278.84	521.15	73.36
Price / Cash	8.01	125.35	43.18	55.00
Price / Book	-32.01	6.90	9.98	7.00
Net Income	$682.64M	$24.23M	$3.55B	$335.16M
7 Day Performance	-4.03%	0.59%	0.42%	-0.29%
1 Month Performance	-1.19%	-0.61%	0.00%	1.15%
1 Year Performance	51.03%	63.26%	34.99%	34.79%

PTC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PTCT PTC Therapeutics	3.7512 of 5 stars	$69.79 -1.7%	$88.36 +26.6%	+50.5%	$5.79B	$1.73B	N/A	1,410	Insider Trade
INSM Insmed	3.4793 of 5 stars	$107.15 -1.8%	$210.95 +96.9%	+57.5%	$23.66B	$606.42M	N/A	1,664	Positive News
BNTX BioNTech	3.684 of 5 stars	$88.85 -0.8%	$130.60 +47.0%	-11.2%	$22.65B	$3.25B	N/A	7,807	Analyst Forecast
ROIV Roivant Sciences	2.3108 of 5 stars	$28.55 -2.5%	$30.55 +7.0%	+193.6%	$20.96B	$29.05M	N/A	860	Trending News Earnings Report Upcoming Earnings Analyst Forecast Options Volume High Trading Volume
MRNA Moderna	1.4044 of 5 stars	$48.11 -1.9%	$35.73 -25.7%	+71.9%	$19.46B	$1.94B	N/A	4,700	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PTCT) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PTC Therapeutics (PTCT) Competitors

PTCT vs. INSM, BNTX, ROIV, MRNA, and VTRS

How does PTC Therapeutics compare to Insmed?

Summary

How does PTC Therapeutics compare to BioNTech?

Summary

How does PTC Therapeutics compare to Roivant Sciences?

Summary

How does PTC Therapeutics compare to Moderna?

Summary

How does PTC Therapeutics compare to Viatris?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PTC Therapeutics (PTCT) Competitors

PTCT vs. INSM, BNTX, ROIV, MRNA, and VTRS

How does PTC Therapeutics compare to Insmed?

Do analysts prefer INSM or PTCT?

Which has higher earnings & valuation, INSM or PTCT?

Does the media favor INSM or PTCT?

Which has more volatility & risk, INSM or PTCT?

Is INSM or PTCT more profitable?

Summary

How does PTC Therapeutics compare to BioNTech?

Do analysts recommend BNTX or PTCT?

Is BNTX or PTCT more profitable?

Which has more risk and volatility, BNTX or PTCT?

Do institutionals and insiders have more ownership in BNTX or PTCT?

Which has preferable valuation and earnings, BNTX or PTCT?

Does the media prefer BNTX or PTCT?

Summary

How does PTC Therapeutics compare to Roivant Sciences?

Which has more volatility & risk, ROIV or PTCT?

Does the media refer more to ROIV or PTCT?

Do analysts rate ROIV or PTCT?

Do institutionals & insiders believe in ROIV or PTCT?

Which has preferable earnings and valuation, ROIV or PTCT?

Is ROIV or PTCT more profitable?

Summary

How does PTC Therapeutics compare to Moderna?

Do analysts recommend PTCT or MRNA?

Do insiders & institutionals have more ownership in PTCT or MRNA?

Which has more volatility & risk, PTCT or MRNA?

Does the media prefer PTCT or MRNA?

Which has better valuation & earnings, PTCT or MRNA?

Is PTCT or MRNA more profitable?

Summary

How does PTC Therapeutics compare to Viatris?

Which has higher earnings and valuation, PTCT or VTRS?

Which has more risk and volatility, PTCT or VTRS?

Do analysts recommend PTCT or VTRS?

Is PTCT or VTRS more profitable?

Do insiders and institutionals have more ownership in PTCT or VTRS?

Does the media prefer PTCT or VTRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT vs. The Competition

PTC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools